Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur, inc.; distributor: zuellig pharma corporation - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2024 strain - suspension for injection (im/sc) - multicomponent/0.5ml

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline phils inc - influenza vaccine (split virion, inactivated) northern hemisphere 2013-2014 strain - suspension for injection im/sc - 15mcg / 0.5ml

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation - influenza vaccine (split virion, inactivated, 2017 southern hemisphere strain) - suspension for deep sc/im injection (single dose)

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation - influenza vaccine (split virion, inactivated, 2017 southern hemisphere strain) - suspension for deep sc/im injection (multiple dose)

Australia - English - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - influenza virus haemagglutinin, quantity: 15 microgram/ml - injection, suspension - excipient ingredients: trometamol; water for injections; sodium chloride; polysorbate 80 - pandemic influenza vaccine h5n1 baxter is indicated for prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (ha per dose a(h5n1)(a/vietnam/1203/2004)) - suspension for injection - 7.5 mcg/0.5ml - active: influenza vaccine whole virion, vero cell derived, inactivated 7.5ug (ha per dose a(h5n1)(a/vietnam/1203/2004)) excipient: polysorbate 80 sodium chloride trometamol water for injection - active immunisation against h5n1 subtype of influenza a virus. this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards as well as immunocompromised and chronically ill subjects following administration of two doses of vaccine prepared with h5n1 subtype strains. vepacel may only be marketed or distributed in accordance with the directives contained in the current version of the new zealand influenza pandemic action plan.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - purified antigen fractions of inactivated split virions - a/indonesia/05/2005 (h5n1)/pr8-ibcdc-rg2 - injection, emulsion - 3.75 µg haemagglutinin/0.25 ml - purified antigen fractions of inactivated split virions - a/indonesia/05/2005 (h5n1)/pr8-ibcdc-rg2 3.75 µg haemagglutinin/0.25 ml

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2024 strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin

Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) 2024 southern hemisphere strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains: a/victoria/2570/2019 ivr-215(hini)-15 mcg* a/darwin/9/2021 san-010 (h3n2)-15 mcg*

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection